

# Feline primary nonhematopoietic malignant liver tumors: A multicenter retrospective study (2000-2021)

**Running title:** Feline primary malignant liver tumors

Mag. Viktoria Brandstetter<sup>1</sup>

Jarno M. Schmidt Dr.med.vet., DECVIM-CA<sup>2</sup>

Laurent Findji DVM, MS, DECVS, MRCVS<sup>3</sup>

Laura E. Selmic, BVetMed (Hons), MPH, DACVS-SA, DECVS, ACVS Founding Fellow, Surgical Oncology, ACVS Founding Fellow, Maxillofacial and Oral Surgery<sup>4</sup>

Daniela Murgia DVM, GPCert (SASTS), GPCert (Oncology), DECVS, MRCVS<sup>5</sup>

Carlos H. de Mello Souza DVM, MS, DACVIM-Oncology, DACVS-SA, ACVS Fellow of Surgical Oncology<sup>6</sup>

Lea M. Liehmann Dr.med.vet., DECVS, MRCSV<sup>7</sup>

Henry L'Eplattenier Dr.med.vet, PhD, DECVS, MRCVS<sup>8</sup>

Mag.phil. Alexander Tichy Dr.rer.nat.<sup>9</sup>

Simona Vincenti DVM, DECVS, MRCVS<sup>1</sup>

<sup>1</sup>Department of Clinical Veterinary Medicine, Vetsuisse Faculty, University of Bern, Bern, Switzerland

<sup>2</sup>Department of Oncology, Small Animal Clinic Hofheim, Hofheim am Taunus, Germany

<sup>3</sup>Fitzpatrick Referrals Oncology and Soft Tissue, Guildford, United Kingdom

<sup>4</sup>Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine, Columbus, Ohio, United States of America

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](https://doi.org/10.1111/vco.12874). Please cite this article as doi: [10.1111/vco.12874](https://doi.org/10.1111/vco.12874)

This article is protected by copyright. All rights reserved.

<sup>5</sup>Surgical Department, Dick White Referrals, Cambridgeshire, United Kingdom

<sup>6</sup>Department of Small Animal Clinical Sciences, University of Florida, Gainesville, Florida, United States of America

<sup>7</sup>Department of Small Animal Surgery, Ophthalmology, Dentistry and Physiotherapy, University of Veterinary Medicine Vienna, Vienna, Austria

<sup>8</sup>Southfields Veterinary Specialists, Laindon, United Kingdom

<sup>9</sup>Department of Biomedical Sciences, Platform Bioinformatics and Biostatistics, University of Veterinary Medicine Vienna, Vienna, Austria

#### **Correspondence:**

Simona Vincenti, Department of Clinical Veterinary Medicine, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

E-mail: [simona.vincenti@vetsuisse.unibe.ch](mailto:simona.vincenti@vetsuisse.unibe.ch)

#### **Acknowledgments**

The authors express their gratitude to all participating institutions, in particular to the Small Animal Clinic Hofheim, which contributed the majority of cases. We also wish to thank Vincent Wavreille for his contribution to the initial study design and Alexander Tichy for his support throughout the statistical analyses.

#### **Conflict of Interests Statement:**

The authors of this manuscript declare that they have no competing interests financial or non-financial that might have influenced their interpretation or presentation of the data presented in this manuscript.

### Cell Line Validation Statement

No cell lines were used in the current study.

### Ethical Statement

The work described in this manuscript involved the use of non-experimental animals only (including owned or unowned animals and data from prospective or retrospective studies).

Established internationally recognized high standards ('best practice') of individual veterinary clinical patient care were followed. Ethical approval from a committee was therefore not specifically required for publication in VCO.

## Abstract

There is scant literature on primary nonhematopoietic malignant liver tumors (PMLT) in cats. In this retrospective study, medical data of 40 cats diagnosed with PMLT were reviewed over a period of 22 years (2000-2021). The most frequent epithelial tumors were hepatocellular (42.5%) and bile duct carcinomas (32.5%), only six (15%) cats had mesenchymal tumors.

The median age was 13 years and clinical signs commonly included ano-/hyporexia (62.5%), apathy/lethargy (52.5%), weight loss (42.5%) and vomiting (35%). At initial diagnosis, metastases were confirmed in 1 (2.5%) and suspected in three (7.5%) cats. Massive was the most frequent morphology (75%). Most intrahepatic tumors were left-sided (54.2%) with the left medial lobe being primarily affected (25%). Extrahepatic tumors were rare (5%). In 34 (85%) cats, liver lobectomy was performed (surgery group), four (10%) were treated palliatively (non-surgery group), and two (5%) received no treatment. Intraoperative complications occurred in 11.8% with four (15.4%) postoperative deaths. Recurrence was detected in 28.6% at a median of 151 days (range, 79-684 days), while postoperative metastases were suspected in 21.4% at a median of 186 days (range, 79-479 days). The median survival time (MST) was significantly longer in cats of the surgery group (375 days) than in the non-surgery group (16 days) ( $P = 0.002$ ). MST was 868 days for hepatocellular compared to 270 days for bile duct carcinomas ( $P = 0.06$ ). In summary, liver lobectomy is associated with prolonged survival times and good prognosis in cats with hepatocellular, and an acceptable prognosis in cats with bile duct carcinoma.

## Keywords

Cats

Bile duct carcinoma

Hepatocellular

Liver neoplasia

Prognosis

Surgical treatment

## Introduction

Primary nonhematopoietic malignant liver tumors (PMLT) are rarely diagnosed in cats and the existing information on them is based on comparatively small and older studies or single case reports<sup>1-9</sup>, with the largest studies on feline nonhematopoietic neoplasia describing only 12<sup>7</sup> and 14<sup>2</sup> PMLT. According to these limited data, PMLT are most commonly of epithelial origin, and bile duct carcinoma is the most common tumor type. Furthermore, PMLT also include hepatocellular carcinoma, neuroendocrine carcinoma and mesenchymal liver tumors<sup>2,6,7,10,11</sup>. There is scarce data on survival times in cats, but the prognosis after surgery is generally considered poor, as 86% of cats in a study on PMLT<sup>2</sup> and 82.4% of cats with hepatobiliary neuroendocrine carcinomas<sup>9</sup> died or were euthanized before discharge from the hospital. Another study on cats with visceral hemangiosarcoma (which most commonly affected the liver in that study) reported a poor post-surgical MST of 77 days<sup>12</sup>. Survival times for cats with bile duct carcinomas are considered even worse, with all patients dying perioperatively in previous studies<sup>2,8</sup>. However, as in dogs<sup>13</sup>, hepatocellular carcinoma seems to have a more favorable prognosis, and a recent feline study described a median survival of 2.4 years in six surgically treated cats with this tumor type<sup>14</sup>. In recent years, significant progress has been made in preoperative diagnostic imaging, veterinary surgical oncology, and postoperative care, suggesting that much of the existing prognostic information may no longer be accurate. Therefore, we conducted a retrospective, multicenter study to describe clinical and diagnostic findings, frequency distribution of histopathological tumor types and outcome in a larger cohort of cats with PMLT. We hypothesized that the prognosis for cats undergoing treatment for malignant, nonhematopoietic liver neoplasms may not be as dismal as often described.

## Methods

The medical databases of eight veterinary referral institutions from continental Europe, the United Kingdom and the United States were retrospectively reviewed for cats with PMLT that presented between January 1<sup>st</sup>, 2000 and December 31<sup>st</sup>, 2021. Cats were included, if PMLT was confirmed by histopathological examination. Benign and hematopoietic liver tumors were excluded as well as tumors diagnosed by cytology only. Cases with multiple liver masses were included, provided that at least one of them was histopathologically diagnosed as PMLT.

Medical data were reviewed for signalment (age, bodyweight, sex, neuter status, and breed), clinical signs, presurgical laboratory findings (blood results, liver mass fine-needle aspiration cytology and bacterial culture), pre- and postsurgical imaging results (thoracic and abdominal imaging), presence of metastatic disease at time of first presentation (staging), treatment type, surgical procedure, gross morphology (morphologic classification, liver lobe distribution, liver side, maximum tumor diameter in centimeters at the time of diagnosis), histopathology, surgical outcome, follow-up information, time to recurrence or metastasis and survival time (ST). Selected preoperative blood count (CBC) and clinical biochemistry (BC) data included: hematocrit (HCT), white blood cell (WBC) count, platelet (PLT) count, total protein (TP) content, albumin (Alb), serum glucose (Glu), serum alkaline phosphatase (ALP), serum alanine aminotransferase (ALT), blood urea nitrogen (BUN), serum creatinine (CREA), and total bilirubin (T-bil) concentration in SI-units. Date of first presentation, surgery/biopsy sampling, recurrence or metastatic disease and date of death, euthanasia or last follow-up were recorded. Follow-up information was defined as diagnostic procedures performed between surgery date and death, euthanasia, or date of last follow-up.

The outcome of the cats was determined from medical follow-up data (if available) and from telephone calls with referring veterinarians and pet owners. Tumors originating in the hepatic ducts, the cystic duct, or the common bile duct (ductus choledochus) were defined as extrahepatic. Intrahepatic tumors were either classified as massive (single mass in one liver lobe), multifocal nodular (multiple nodules of varying size in more than one liver lobe), or diffuse (diffuse infiltration of all liver lobes)<sup>6,11,15,16</sup>. The location of massive and nodular intrahepatic hepatobiliary tumors was recorded according to Liptak et al. (2004) as either left, central, or right<sup>13</sup>. Left-sided tumors involved the left lateral and medial lobe, or the papillary process of the caudate lobe. Central tumors affected either the right medial or quadrate liver lobes. Right-sided tumors originated either from the right lateral lobe or the caudate process of the caudate lobe<sup>13</sup>. The maximum tumor dimension at the time of diagnosis was determined from the surgery report or from abdominal imaging (CT, ultrasonography) and given as the maximum diameter in centimetres (cm). Intraoperative complications were classified as grade I-IV (CLASSIC system<sup>17</sup>) ranging from no deviation of the ideal operative course to patient death. Postoperative complications were classified as mild, moderate, severe, and those leading to postoperative death (level 4) according to the Accordion classification reported by Follette et al. (2019)<sup>17</sup>.

### Statistical Analysis

All statistical data were analyzed under supervision of a biostatistician using a commercially available statistical software program (IBM SPSS Statistics Version 28.0.0.0) and Microsoft Excel. Descriptive statistics and frequency tables were used to summarize the potential variables of interest. Normal distribution of continuous variables was assessed visually and using the Shapiro-Wilks test for normality. Normally distributed values were described with



mean  $\pm$  standard deviation, variables which did not meet the assumption of normal distribution by median and the range from minimum to maximum value. Categorical variables were described as the proportion of the study population and percentage. The Mann-Whitney-U test (for continuous variables) and the Pearson Chi-Square test ( $\chi^2$ ) (for categorical variables) were used to determine if there were any significant differences between the most representative histopathological groups (hepatocellular carcinoma, bile duct carcinoma) for age, bodyweight, clinical symptoms, blood results, morphologic classification, liver side, tumor diameter and complete excision. The Pearson Chi-Square test ( $\chi^2$ ) was further used to determine the correlation between tumor diameter and inoperability as well as complete excision and between complete excision and local recurrence. To compare outcome and survival data, cats were further allocated into a (curative-intent) surgery and a non-surgery (conservative treatment) group. The time to recurrence or metastasis was defined as the number of days from the date of definitive diagnosis (liver lobectomy or biopsy sampling) to the day of recurrence or metastatic disease (based on imaging findings and cytological examination). The survival time (ST) was defined as the interval from the date of definitive diagnosis until death or euthanasia. The Kaplan-Meier analysis with log rank was used to compare the survival time between different treatment and histopathological groups and between completely versus incompletely excised tumors. Cats without treatment ( $n = 2$ ) and animals euthanized intraoperatively ( $n = 8$ ), were excluded from these analyses. Cats that were still alive at the closing date of data collection or lost to follow-up were censored for survival analyses at the last known date alive. For all statistical analyses, a  $P$ - value of  $\leq 0.05$  was considered significant.

## Results

### Type & frequency distribution of tumors

Forty cats across 8 institutions were included in the study. Thirty-four of 40 (85%) PMLT were histopathologically diagnosed after surgical excision of the masses (liver lobectomy). In a minority of cases (6/40; 15%) diagnosis was made by collecting incisional biopsy samples via laparotomic incisional liver biopsies (4/40; 10%) or TruCut biopsies (2/40; 5%). On histopathology, 34/40 (85%) tumors were of epithelial origin and 6/40 (15%) were mesenchymal. The most frequent epithelial tumors were 17/40 (42.5%) hepatocellular carcinomas and 13/40 (32.5%) bile duct carcinomas (see Table 1).

### Signalment, Clinical characteristics

The median age at the time of first presentation was 13 years (range, 2.6-18.2 years) and 75% of the cats were older than 10 years. The median bodyweight was 4.1 kg (range, 1.9-11 kg). No statistically significant differences in age ( $P = 0.41$ ) or bodyweight ( $P = 0.75$ ) were found among histopathological tumor types. Among the female cats, 3 were intact and 14 were spayed. There were 3 intact male cats and 20 neutered males. The eleven breeds represented in the total data were: 28 domestic short-hair (DSH; 70%), 2 domestic long-hair (DLH; 5%), 2 Maine Coon (5%), and one each of eight other breeds. Information on presenting clinical signs was available from 38/40 (95%). Clinical symptoms were documented in 36/40 (90%) cats, whereas 2/40 (5%) cats were asymptomatic, and in 2/40 (5%) no information was reported. The most frequent clinical signs were ano- or hyporexia (25/40; 62.5%) and apathy/lethargy (21/40; 52.5%), followed by weight loss (17/40; 42.5%) and vomiting (14/40; 35%). Jaundice was detected in 5/40 (12.5%) cats (3/5 jaundiced cats had a bile duct carcinoma). When comparing the histopathological groups, bile duct

carcinomas caused jaundice more often ( $P = 0.02$ ), whereas hepatocellular carcinomas were more likely to cause vomitus ( $P = 0.04$ ).

## Laboratory findings

### Blood results

Selected preoperative blood count (CBC) and clinical biochemistry (BC) data were available in most cats (38/40; 95%). Anemia was common (15/29; 51.7%), however further characterization of anemia was not available. Five (33.3%) cats had concurrent thrombocytopenia. One out of 33 (3.0%) cats was leucopenic and in 6/33 (18.2%) cats leucocytosis was found (in 4 cats above 25 G/L). Serum total protein (TP) values were decreased in 5/29 (17.2%) cats and albumin was decreased in 9/31 (29.0%). Serum hyperglycemia was reported in 14/27 cats (51.9%), whereas a minority (3/27; 11.1%) was hypoglycemic. Elevation of at least one liver enzyme (alkaline phosphatase (ALP), alanine aminotransferase (ALT)) was recorded in 16/38 (42.1%) cats. Hyperbilirubinemia was present in 22/26 (84.6%) of patients. Clinical jaundice was only observed in 5/40 (12.5%) cats, three of which had marked elevation of total serum bilirubin (above 150  $\mu\text{mol/L}$ ). Blood urea nitrogen (BUN) was decreased in 7/28 (25.0%) and creatinine levels were increased in 8/31 (25.8%) cats. Significantly higher ALT values ( $P = 0.003$ ) were observed in hepatocellular carcinomas compared to bile duct carcinomas. No difference between histopathological groups could be recorded in any other CBC or BC parameter.

### Cytology and bacteriology results

Ultrasound-guided fine-needle aspiration (FNA) biopsies were performed in 23/40 (57.5%) cats. Cytology was non-diagnostic in 6/23 (15%) cases. A cytological diagnosis was assigned in 17/23 cats (bile duct carcinoma ( $n = 5$ ), undefined carcinoma ( $n = 5$ ),

hepatocellular carcinoma ( $n = 2$ ), hepatocellular adenoma ( $n = 1$ ), biliary cystadenoma ( $n = 1$ ), round cell tumor ( $n = 1$ ), undefined sarcoma ( $n = 2$ )). However, cytological diagnoses were consistent with the histopathological results in only 6/17 (35.3%) cases, namely 3 bile duct carcinomas, 2 hepatocellular carcinomas, and 1 undefined carcinoma. Bacterial hepatic/biliary cultures were performed in 1/40 (2.5%) cats and were negative. Twelve out of 40 (30%) cats had peritoneal effusions (transudate ( $n = 1$ ), exudate ( $n = 3$ ), hemorrhagic ( $n = 2$ ), chylous ( $n = 1$ ), undetermined ( $n = 5$ )). One exudate was due to septic bile peritonitis.

### Imaging findings

Thoracic imaging was performed in 31/40 (77.5%) cats including thoracic radiographs in 19/40 (47.5%) cats (two cats had 3-view radiographs) and thoracic computed tomography (CT) in 15/40 (37.5%) cats. Abdominal imaging was available in 38/40 (95%) cats and included radiography in 2/40 (5%) cats, ultrasonography in 33/40 (82.5%) and abdominal CT in 16/40 (40%) patients. In two cases (neuroendocrine carcinoma ( $n = 1$ ), hepatocellular carcinoma ( $n = 1$ )), mesenteric lymphadenomegaly was suspicious for metastatic disease on abdominal ultrasonography at the time of initial presentation, however no cytological evaluation was recorded.

### Treatment

Thirty-four cats (85%) were managed by curative-intent liver lobectomy (“surgery group”). Four cats (10%) were treated conservatively/palliatively (“non-surgery group”), while two (5%) cats received no treatment at all.

The only surgery-related complication during liver lobectomy was hemorrhage (4/34; 11.8%), considered as mild (grade I<sup>17</sup>) in 2/34 (5.9%) and moderate (grade II<sup>17</sup>) in 2/34 (5.9%). The latter two received a blood transfusion postoperatively. Eight out of 34 (23.5%)

cats were euthanized intraoperatively as the liver mass was judged as unresectable (hepatocellular carcinomas ( $n = 2$ ), bile duct carcinoma ( $n = 3$ ), hemangiosarcomas ( $n = 1$ ), undefined carcinoma ( $n = 1$ ) and undefined sarcoma ( $n = 1$ )). Reasons were reported in 5 out of 8 cats and included multilobar distribution ( $n = 2$ ), major involvement of the bile ducts ( $n = 2$ ) and suspected metastatic disease ( $n = 1$ ) and PMLT was confirmed on post-mortem histopathology. In two cases (hepatocellular carcinomas ( $n = 1$ ), hemangiosarcomas ( $n = 1$ )), highly invasive growth, involving major vascular structures prevented complete removal of the mass and resulted in partial liver lobectomy or incisional biopsy, respectively. No significant association was found between tumor diameter and inoperability ( $P = 0.56$ ). Intraoperative deaths related to complications associated with surgery or anesthesia were not reported. An esophageal tube was subsequently placed in 4 cats during surgery due to preoperative anorexia/hyporexia, and 2 cats received an abdominal drainage owing to preoperative ascites. Short-term postoperative complications (during hospitalization) related to surgery were reported in 14/26 (53.9%) cats. Mild complications (6/26; 23.1%) included anorexia/hyporexia (2/26; 7.7%), apathy/lethargy (1/26; 3.9%), retching and esophagitis (1/26; 3.9%), pancreatitis (1/26; 3.9%), and mild postoperative ascites (1/26; 3.9%). In 15.4% (4/26) cats, moderate complications were reported (blood transfusion ( $n = 3$ ), blood transfusion and nasogastric tube ( $n = 1$ )). Four (15.4%) cats died within 1 day after liver lobectomy (hypothermia and hypotension ( $n = 2$ ), hypothermia and anemia ( $n = 1$ ), no details ( $n = 1$ )).

Adjuvant chemotherapy was initiated in one cat with neuroendocrine carcinoma (carboplatin; 240mg/m<sup>2</sup>, IV two times at an interval of 30 days) 2 months postoperatively. A Tyrosine Kinase receptor inhibitor (toceranib phosphate; dosage and duration not noted)

was started 18 months post liver lobectomy in one cat with bile duct carcinoma due to metastatic disease. In one cat of the non-surgery group (hepatocellular carcinoma), metronomic chemotherapy (thalidomide, cyclophosphamide, piroxicam) was started after the biopsy result was obtained.

### Gross tumor morphology

Information on morphologic classification and liver lobe distribution of massive and nodular PMLT is shown in Tables 2 and 3. Invasion of adjacent lobes was noted in 23.3% (7/30) of the massive lesions. Of those, the left medial and left lateral ipsilateral lobes ( $n = 2$ ), as well as the right medial and quadrate lobes ( $n = 2$ ) were most commonly affected. Two tumors involved the extrahepatic bile ducts (bile duct carcinoma ( $n = 1$ ), undefined carcinoma ( $n = 1$ )): one originated from the cystic duct, the other from the common bile duct. Maximum tumor diameter was reported for 31/40 (77.5%) cases and varied from 1-15cm (median 5cm), with 45.2% of them exceeding 5cm. The entire lobe was affected in two cases. There was no statistically significant difference in tumor diameter among histopathological groups ( $P = 0.83$ ).

### Histopathologic findings

Surgical margins were assessed in 30/34 (88.2%) of surgically treated patients. Most tumors 21/30 (70%) were incompletely excised irrespective of histopathological group ( $P = 0.41$ ) or tumor diameter ( $P = 0.90$ ). Complete excision was documented in 9/30 (30%) cats. No significant correlation was found between complete excision and local recurrence ( $P = 0.88$ ). Complete excision was not associated with a longer survival time ( $P = 0.84$ ). Mesenteric lymph node metastases were histopathologically confirmed in 1 hepatocellular carcinoma (2.5%), while in 2 other cases (undefined carcinoma ( $n = 1$ ), bile duct carcinoma ( $n = 1$ ))

(5%) intraperitoneal metastases (peritoneum, mesentery, omentum, spleen) were suspected intraoperatively based on their appearance.

### Follow-up information

Local recurrence was suspected on abdominal ultrasonography in 4/14 (28.6%) cats (bile duct carcinoma ( $n = 1$ ), neuroendocrine carcinoma ( $n = 1$ ), hepatocellular carcinoma ( $n = 1$ ) and fibrosarcoma ( $n = 1$ )). Ultrasound-guided FNA biopsy was consistent with recurrence in the cat with hepatocellular carcinoma. The median time from surgery to recurrence was 151 days (range, 79-684 days; mean 266 days), while the median time from surgery to metastasis (3/14; 21.4%) was 186 days (range, 79-479 days; mean, 248 days). In all three cases (bile duct carcinoma ( $n = 2$ ), fibrosarcoma ( $n = 1$ ), the metastases were suspected intraperitoneal (omentum, small intestine, diffuse) on abdominal ultrasonography, with cytological confirmation in only one cat (bile duct carcinoma).

The median follow-up time for censored cases (still alive or lost to follow-up) from the date of definitive diagnosis was 457 days (range, 246-962 days).

### Survival time

In the surgery group, the median survival time (MST) was 375 days (range, 0-2,033 days; mean, 732.9 days) from the date of definitive diagnosis (liver lobectomy). In the non-surgery group, MST was 16 days (range, 0 to 81 days; mean, 33.8 days) from the date of definitive diagnosis (biopsy sampling). Cats in the surgery group had significantly longer survival times from the date of definitive diagnosis ( $P = 0.002$ ) than cats in the non-surgery group. Cats with hepatocellular carcinomas had an MST of 868 days (range, 1 to 2,033; mean, 987.9 days) from the date of definitive diagnosis. In contrast, bile duct carcinomas had an MST of 270 days (range, 0 to 889; mean, 338.2 days) from the date of definitive diagnosis. However,

the difference in MST was not statistically significant ( $P = 0.06$ , respectively). The survival analysis included one cat with neuroendocrine carcinoma, which had a survival of 246 days from date of definitive diagnosis. Primary mesenchymal tumors had a median survival time of 16 days (range, 1 to 427; mean, 143.3 days) from date of diagnosis.

The Kaplan-Meier survival data of the most representative histopathological and treatment groups are outlined in Figures 1 and 2. At the closing date of data collection, 2 (7.7%) cats of the surgery group were still alive, whereas 15 (57.7%) cats had died or been euthanized, and nine (34.6%) cats of the surgery group were lost to follow-up. Of all the cats with local recurrence or metastatic disease, none were reported to be alive at the closing date of data collection (dead ( $n = 3$ ), lost to follow-up ( $n = 3$ )). None of the patients of the non-surgery group were still alive.



## Discussion

Primary nonhematopoietic malignant liver tumors (PMLT) are rarely diagnosed in cats. In this retrospective study, 40 cats with PMLT were presented at their respective institutions within a period of 22 years (2000-2021). Our findings suggest that liver lobectomy represents an effective treatment option for PMLT, with prolonged survival times for cats with hepatocellular carcinoma and bile duct carcinoma.

Signalment, clinical presentation, and laboratory findings of cats with PMLT in the present study were largely consistent with previous reports on feline liver tumors<sup>2,5,7,11,14,16,18</sup>. Further, while hematopoietic tumors (e.g. hepatic lymphoma) can occur at any age and even in (very) young cats, PMLT are expected to predominantly occur in middle-aged to older cats<sup>2,3,7,9,14,19</sup>. Accordingly, in the present study 75% of cats were older than 10 years. Clinical signs and laboratory findings of cats with PMLT in the current study were typically non-specific and notably jaundice (12.5%) and liver enzyme elevation (42.1%) were present in only a minority of patients. While serum bilirubin level was only assessed in 26/40 (65%) cats, it was elevated in 84.6% of them and may be a more sensitive marker for PMLT than liver enzyme elevations. Cytological examination was of limited use for definitive diagnosis of PMLT as it was consistent with the histopathological results in only 6/17 (35.3%) cases. Similar results have been found in previous studies, which reported a rather low accuracy ranging from 33% to 51%<sup>14,20-22</sup>. The high accuracy of 86%, reported by Roth (2001)<sup>23</sup> has been critically discussed in an earlier study, as their not fully specified method of cytological specimen acquisition may have positively biased the results<sup>20</sup>. Thus, cytological evaluation may be useful, but results need to be interpreted with caution<sup>21</sup>. Histopathological examination remains the gold standard, especially in poorly exfoliative tumors and cavitated

lesions<sup>14,18,21,23</sup>.

In the current study, hepatocellular carcinoma was most common (42.5%). Primary hepatic sarcomas were less frequently diagnosed in this study (15%) and hemangiosarcoma was the most common mesenchymal tumor type, similar to previous reports<sup>2,4,6,7</sup>. There is no consensus about the most common malignant hepatobiliary tumor in cats. Whereas an older study reported that hepatocellular carcinomas were the most frequent<sup>4</sup>, more recent studies described bile duct carcinomas as the most common PMLT in cats<sup>2,6,7,10</sup>. Massive was the most common morphological manifestation in all histopathological groups. This is in contrast to previous studies in cats which reported a majority of diffuse morphology with most malignant tumors (58.3%)<sup>6</sup>. In the present study, 54.2% of the intrahepatic tumors were left-sided. This finding differs from a previous study in cats, in which the right-sided lobes were affected in 46.7%<sup>14</sup>, but is consistent with the results in dogs<sup>13,15,24,25</sup>. Unlike in dogs however<sup>25</sup>, the left medial lobe of the liver was primarily affected in our study population (25%), followed by the left lateral and right medial liver lobes (each 22.5%). Malignant tumors involving the extrahepatic bile ducts were rare in our study (5%), while previous studies reported higher rates (13.3% to 52.9%)<sup>2,4,6,9</sup>. However, similarly low rates of 2%<sup>15</sup> and 8.3%<sup>24</sup> have been reported in canine studies.

The metastatic rate and pattern depends on the type and morphology of the tumor<sup>16,18</sup>. In dogs, metastatic rates from 4.8% to 61% have been reported in massive hepatocellular carcinomas<sup>13,15,25</sup>, 88% in bile duct carcinomas<sup>15,24</sup>, 86% in sarcomas<sup>15</sup> and 93% in hepatic carcinoids<sup>15</sup>. The most commonly reported metastatic sites are regional lymph nodes, lungs and peritoneum for epithelial and spleen for mesenchymal tumors<sup>13,15,24,25</sup>. For cats limited information is available on metastatic rates and sites in malignant hepatobiliary tumors.

Patnaik (1992) reported extrahepatic metastases in 56% of epithelial neoplasms in cats, with the most common metastatic sites being intraperitoneal (>50% of the cases), lung, lymph nodes and spleen<sup>6</sup>. According to some reports, hepatocellular carcinomas have a lower metastatic rate than biliary neoplasms<sup>6,14</sup>, whereas hemangiosarcomas and hepatobiliary neuroendocrine carcinomas in cats have a high metastatic potential<sup>1,6,9,12</sup>. In the present study, mesenteric lymph node metastases were histopathologically confirmed in 1 (2.5%) cat with hepatocellular carcinoma and suspected on ultrasonography or intraoperatively in another three cases (hepatic lymph nodes ( $n = 1$ ), intraperitoneal ( $n = 2$ )) (7.5%) at the time of presentation/diagnosis. Therefore, the metastatic rate at time of diagnosis may range between 2.5% and 10%. Three (21.4%) cats developed intraperitoneal metastatic disease after a median of 186 days from surgery (bile duct carcinoma ( $n = 2$ ), fibrosarcoma ( $n = 1$ )). Metastasis rates are low but may have been underestimated in this study due to inconsistent staging procedures and postoperative follow-up. Screening for pulmonary metastases<sup>1,16,18</sup> by CT was performed in only 37.5% (15/40) cats and by 3 view radiographs in a minority of 5% (2/40) cats. Abdominal ultrasonography is commonly recommended for the identification and characterization of hepatobiliary neoplasms in small animals<sup>16</sup> and was used in most cases (82.5%). However, ultrasonography has severe limitations for staging and surgical planning<sup>12,26</sup>. Therefore, cross-sectional imaging (MRI, CT) should be considered for more accurate assessment, especially in diffuse or multifocal hepatobiliary diseases<sup>1,13,16,18,26,27</sup>. In our study, a large proportion of cats (23.5%) were euthanized at the time of surgery owing to unresectable neoplasms. Apart from the fact that resectability also depends on the surgeon's experience and expertise, none of these cases had a preoperative

CT or MRI scan. We hypothesize that outcomes in some cases may have been different if advanced imaging was done prior to surgery.

For massive hepatic neoplasms, surgical resection is the treatment of choice<sup>1,5,11,16</sup> even though, due to scant literature, the true benefit is still largely undetermined. In the present study, there was a moderate rate (11.8%) of surgical complications but no intraoperative deaths. However, four (15.4%) cats died within one day after liver lobectomy. This is less than the 86% of cats with PMLT that died during surgery or hospitalization in an older study<sup>2</sup>. In dogs, surgical complications of 28.6% with an intraoperative mortality rate of 4.8% in hepatocellular carcinomas<sup>13</sup> and 20% in extrahepatic biliary neoplasia<sup>28</sup> have been reported. A previous study in cats with PMLT described a poor MST of 0.1 months (range, <1 day to 4 months)<sup>2</sup>. We report an MST of 375 days from the date of diagnosis for the surgery group, which was significantly higher, compared to 16 days in the non-surgery group (Figure 1). We found a prolonged MST of 868 days (2.4 years) from the date of diagnosis in the 14 hepatocellular carcinomas of the surgery-group, which is consistent with a recent study by Goussev et al. (2016). Interestingly, they described a similar MST of 2.4 (1 to 6.5) years in six surgically treated cats with histopathological diagnosis of hepatocellular carcinoma<sup>14</sup>. In comparison, an MST of > 1,460 days (4 years) has been reported for surgically treated dogs with massive hepatocellular carcinoma<sup>13</sup>. In the present study, bile duct carcinomas had a shorter, albeit statistically not significantly different, MST of 270 days (0.7 years), compared to hepatocellular carcinomas (Figure 2). In comparison, an earlier study reported that all 10 cats with bile duct carcinoma died or were euthanized during surgery or hospitalization<sup>2</sup>. Equally poor survival has been reported for hepatobiliary neuroendocrine carcinomas, with 14/17 cats dying perioperatively<sup>9</sup>. In our study, only one

cat with neuroendocrine carcinoma had adequate follow-up after surgery and died 246 days after surgery.

This study has several limitations. Even though it is the largest study on feline PMLT to date, the number of tumors in the different histopathological groups are still comparatively small, which precluded statistical comparisons between all groups. Further, because of its retrospective nature, cats did not receive standardized protocols for staging, treatment, or follow-up, and treatment decisions were influenced by the preferences and habits of individual clinicians. Cats that were euthanized intraoperatively were excluded from survival analysis, which may have biased the results toward inclusion of cats with better prognosis. However, better preoperative planning by cross-sectional imaging may have resulted in a better outcome in some of those euthanized cats.

## Conclusions and clinical relevance

This study provides valuable information on a poorly characterized set of malignant neoplasms in cats and may improve therapeutic decision-making. Clinical signs and laboratory findings of cats with PMLT have typically been non-specific and although hyperbilirubinemia and cytological tumour diagnosis may provide some indication, the diagnosis is based on histopathological confirmation. Surgical intervention is associated with a prolonged survival time and good prognosis in cats with hepatocellular carcinoma and acceptable survival times in cats with bile duct carcinoma. Therefore, in general, such treatment should be considered and discussed with the owners. The overall local recurrence and metastatic rates in surgically treated cats with PMLT appear to be low. However, the small case numbers and non-standardized protocols of this retrospective study do not allow definitive conclusions to be drawn. Since preoperative abdominal and thoracic CT scans are nowadays increasingly performed in most hospitals for staging and surgical planning, we encourage further investigations on their effect towards a better patient selection.

## References

1. Balkman C. Hepatobiliary neoplasia in dogs and cats. *Vet Clin North Am Small Anim Pract.* 2009;39(3):617-625. doi:10.1016/j.cvsm.2009.01.001
2. Lawrence HJ, Erb HN, Harvey HJ. Nonlymphomatous hepatobiliary masses in cats: 41 cases (1972 to 1991). *Vet Surg.* 1994;23(5):365-368. doi:10.1111/j.1532-950X.1994.tb00496.x
3. Schmidt RE, Langham RF. A survey of feline neoplasms. *J Am Vet Med Assoc.* 1967;151:1325-1328.
4. Patnaik AK, Liu SK, Hurvitz AI, McClelland AJ. Nonhematopoietic neoplasms in cats. *J Natl Cancer Inst.* 1975;54(4):855-860.
5. Hammer AS, Sikkema DA. Hepatic neoplasia in the dog and cat. *Vet Clin North Am Small Anim Pract.* 1995;25(2):419-435. doi:10.1016/S0195-5616(95)50035-X
6. Patnaik AK. A morphologic and immunocytochemical study of hepatic neoplasms in cats. *Vet Pathol.* 1992;29(5):405-415. doi:10.1177/030098589202900506
7. Post G, Patnaik AK. Nonhematopoietic hepatic neoplasms in cats: 21 cases (1983-1988). *J Am Vet Med Assoc.* 1992;201(7):1080-1082.
8. Diogenes TT, Rocha MA, Sampaio KO, Olinda RG, Nunes Pinheiro DCS, Sousa Filho RP. Primary gallbladder adenocarcinoma in a cat. *Acta Sci Vet.* 2020;48. doi:10.22456/1679-9216.101267
9. Patnaik AK, Lieberman PH, Erlandson RA, Antonescu C. Hepatobiliary neuroendocrine carcinoma in cats: A clinicopathologic, immunohistochemical, and ultrastructural study of 17 cases. *Vet Pathol.* 2005;42(3):331-337. doi:10.1354/vp.42-3-331
10. Argenta FF, Mello LS, Caprioli RA, Pavarini SP, Driemeier D, Sonne L. Pathological and immunohistochemical aspects of primary hepatobiliary neoplasms in cats. *Pesqui Veterinária Bras.* 2020;40(1):46-54. doi:10.1590/1678-5150-pvb-6071
11. Johnson SE, Sherding RG. Diseases of the liver and biliary tract. In: *Saunders Manual of Small Animal Practice.* 3rd ed. Elsevier; 2006:747-809. doi:10.1016/B0-72-160422-6/50073-5
12. Culp WTN, Drobatz KJ, Glassman MM, Baez JL, Aronson LR. Feline visceral hemangiosarcoma. *J Vet Intern Med.* 2008;22(1):148-152. doi:10.1111/j.1939-1676.2008.0022.x

13. Liptak JM, Dernell WS, Monnet E, et al. Massive hepatocellular carcinoma in dogs: 48 cases (1992-2002). *J Am Vet Med Assoc*. 2004;225(8):1225-1230. doi:10.2460/javma.2004.225.1225
14. Goussev SA, Center SA, Randolph JF, Kathrani A, Butler BP, McDonough SP. Clinical characteristics of hepatocellular carcinoma in 19 cats from a single institution (1980–2013). *J Am Anim Hosp Assoc*. 2016;52(1):36-41. doi:10.5326/JAAHA-MS-6289
15. Patnaik AK, Hurvitz AI, Lieberman PH. Canine hepatic neoplasms: A clinicopathologic study. *Vet Pathol*. 1980;17(5):553-564. doi:10.1177/030098588001700504
16. Liptak JM. Hepatobiliary tumors. In: Vail DM, Thamm DH, Liptak JM, ed. *Withrow & MacEwen's Small Animal Clinical Oncology*. 6th ed. Elsevier; 2019:454-459.
17. Follette CM, Giuffrida MA, Balsa IM, et al. A systematic review of criteria used to report complications in soft tissue and oncologic surgical clinical research studies in dogs and cats. *Vet Surg*. 2020;49(1):61-69. doi:10.1111/vsu.13279
18. Selmic LE. Hepatobiliary neoplasia. *Vet Clin North Am Small Anim Pract*. 2017;47(3):725-735. doi:10.1016/j.cvsm.2016.11.016
19. Gabor L, Malik R, Canfield P. Clinical and anatomical features of lymphosarcoma in 118 cats. *Aust Vet J*. 1998;76(11):725-732. doi:10.1111/j.1751-0813.1998.tb12300.x
20. Wang KY, Panciera DL, Al-Rukibat RK, Radi ZA. Accuracy of ultrasound-guided fine-needle aspiration of the liver and cytologic findings in dogs and cats: 97 cases (1990–2000). *J Am Vet Med Assoc*. 2004;224(1):75-78. doi:10.2460/javma.2004.224.75
21. Bahr KL, Sharkey LC, Murakami T, Feeney DA. Accuracy of US-guided FNA of focal liver lesions in dogs: 140 cases (2005–2008). *J Am Anim Hosp Assoc*. 2013;49(3):190-196. doi:10.5326/JAAHA-MS-5851
22. Cole TL, Center SA, Flood SN, et al. Diagnostic comparison of needle and wedge biopsy specimens of the liver in dogs and cats. *J Am Vet Med Assoc*. 2002;220(10):1483-1490. doi:10.2460/javma.2002.220.1483
23. Roth L. Comparison of liver cytology and biopsy diagnoses in dogs and cats: 56 cases. *Vet Clin Pathol*. 2001;30(1):35-38. doi:10.1111/j.1939-165X.2001.tb00254.x
24. Patnaik AK, Hurvitz AI, Lieberman PH, Johnson GF. Canine bile duct carcinoma. *Vet Pathol*. 1981;18(4):439-444. doi:10.1177/030098588101800403
25. Patnaik AK, Hurvitz AI, Lieberman PH, Johnson GF. Canine hepatocellular carcinoma. *Vet Pathol*. 1981;18(4):427-438. doi:10.1177/030098588101800402



26. Wormser C, Reetz JA, Giuffrida MA. Diagnostic accuracy of ultrasound to predict the location of solitary hepatic masses in dogs: Ultrasound localization of hepatic masses in dogs. *Vet Surg*. 2016;45(2):208-213. doi:10.1111/vsu.12436
27. Marolf AJ. Computed tomography and MRI of the hepatobiliary system and pancreas. *Vet Clin North Am Small Anim Pract*. 2016;46(3):481-497. doi:10.1016/j.cvsm.2015.12.006
28. Mehler SJ, Mayhew PD, Drobatz KJ, Holt DE. Variables Associated with Outcome in Dogs Undergoing Extrahepatic Biliary Surgery: 60 Cases (1988-2002). *Vet Surg*. 2004;33(6):644-649. doi:10.1111/j.1532-950X.2004.04087.x

## Tables

Table 1. Frequency distribution of histopathological tumor types in 40 cats with PMLT<sup>†</sup>.

Diagnosis	Number (n)	Percentage of the study population (%)
<b>Hepatocellular carcinoma</b>	17	42.5
<b>Bile duct carcinoma</b>	13	
Intrahepatic	12	30
Extrahepatic	1	2.5
<b>Undefined carcinoma</b>	2	
Intrahepatic	1	2.5
Extrahepatic	1	2.5
<b>Neuroendocrine carcinoma</b>	2	5
<b>Primary mesenchymal tumors</b>	6	
Hemangiosarcoma	4	10
Fibrosarcoma	1	2.5
Undefined sarcoma	1	2.5
<b>Total</b>	40	100

<sup>†</sup>PMLT= primary nonhematopoietic malignant liver tumors.

Table 2. Morphologic classification of PMLT<sup>†</sup> in cats.

Tumor type	Number (%)			
	Massive	Nodular	Diffuse	Total
Hepatocellular carcinoma	13 (76.5)	2 (11.8)	2 (11.8)	17 (100)
Bile duct carcinoma	9 (69.2)	2 (15.4)	2 (15.4)	13 (100)
Neuroendocrine carcinoma	2 (100)	0 (0)	0 (0)	2 (100)
Sarcoma	5 (83.3)	0 (0)	1 (16.7)	6 (100)
Other	1 (50)	0 (0)	1 (50)	2 (100)
Total	30 (75)	4 (15)	6 (15)	40 (100)

<sup>†</sup>PMLT= primary nonhematopoietic malignant liver tumors.

Table 3. Liver lobe distribution of massive and nodular PMLT<sup>†</sup> in cats.

Tumor type	Number (n)										
	intrahepatic							extrahepatic			
	LL	LM	RL	RM	C	Q	Left	Central	Right	NC	
Hepatocellular carcinoma	5	3	2	6	1	2	7	5	1	4	0
Bile duct carcinoma	3	4	0	3	4	2	4	4	0	5	1
Neuroendocrine carcinoma	1	1	0	0	1	1	0	0	0	2	0
Sarcoma	0	2	1	0	0	0	2	0	1	3	0
Other	0	0	0	0	0	0	0	0	0	2	1
Total	9	10	3	9	6	5	13	9	2	16	2

<sup>†</sup>PMLT=primary nonhematopoietic malignant liver tumors.

LL=left lateral lobe. LM=left medial lobe. RL=right lateral lobe. RM=right medial lobe.

C=caudate lobe. Q=quadrate lobe. NC=not classified.

## Illustrations (Figures)




Figure 1. Kaplan-Meier curves for survival time from date of definitive diagnosis in cats with primary nonhematopoietic malignant liver tumors, treated with surgery (“surgery group”, solid green line; median 375 days;  $n = 23$ ) compared to those treated palliatively (“non-surgery group”, dashed black line; median 16 days;  $n = 4$ ). MST was significantly different ( $P = 0.003$ ).




Figure 2. Kaplan-Meier curves for survival time from date of definitive diagnosis in hepatocellular carcinomas (solid green line; median 868 days;  $n = 14$ ) compared to bile duct carcinomas (dashed black line; median 270 days;  $n = 9$ ). MST was not significantly different ( $P = 0.06$ ).

## Conflict of Interests:

The authors of this manuscript declare that they have no competing interests financial or non-financial that might have influenced their interpretation or presentation of the data presented in this manuscript.